Platelet refractoriness continues to be a problem for thrombocytopenic patients because the
risk of a major spontaneous or life-threatening bleed significantly increases when platelet …

Platelet transfusion is a common practice in onco-hematologic patients for preventing or
treating hemorrhages. Platelet concentrates can be transfused with therapeutic or …

Approximately 20% of patients receiving multiple platelet transfusions develop platelet
alloantibodies, which can be directed against human leukocyte antigens (HLA) and, to a …

Background The formation of alloantibodies directed against class I human leukocyte
antigens (HLA) continues to be a clinically challenging complication after platelet …

BACKGROUND Platelet transfusion–refractoriness is a challenging and expensive clinical
scenario seen most often in patients with hematologic malignancies. Although the majority of …

Management of the Platelet Refractory Patient - Hematology/Oncology Clinics Skip to Main
Content Advertisement Hematology/Oncology Clinics Log in Register Log in Subscribe Claim …

Platelet concentrates account for near 10% of all labile blood components but are
responsible for more than 25% of the reported adverse events. Besides factors related to …

Platelet transfusions have contributed to the revolutionary modern treatment of
hypoproliferative thrombocytopenia. Despite the long-term application of platelet transfusion …

Refractoriness to platelet transfusion is a common clinical problem encountered by the
transfusion medicine specialist. It is well recognized that most causes of refractoriness to …

Hematopoietic stem cell transplantation has been considered a risk factor for development
of platelet transfusion refractoriness. The objective of this study was to assess the platelet …